Michael Egholm, Ph.D.
Michael Egholm, Ph.D., is the Chief Technology Officer of Danaher Life Sciences and currently leads Danaher’s corporate venture fund since 2017. Previously, Dr. Egholm was the President of Biopharmaceuticals at Pall Corporation since 2014, and he joined Pall as its Chief Technology Officer in 2010. Dr. Egholm has over 25 years of proven leadership in developing and commercializing innovative technologies and previously served as Chief Technology Officer a at 454 Life Sciences Corporation; the first company to successfully commercialize Next Gen Sequencing (NGS). Prior to joining 454, Dr. Egholm held senior R&D positions with Molecular Staging and Applied Biosystems. Furthermore, Dr. Egholm is an elected member of the Royal Danish Academy of Sciences and Letters, a named inventor on numerous patents and co-author of many high profile papers. Michael earned his Ph.D. In chemistry from University of Copenhagen.